TRX-4 (TolerRx Inc).
TolerRx Inc, under license from BTG plc, is developing TRX-4, an anti-CD3 humanized monoclonal antibody for the potential treatment of type 1 diabetes and psoriasis. Phase II trials of the therapeutic antibody in type 1 diabetes have been completed and the company is planning a pivotal phase III trial for this indication. TolerRx is also enrolling psoriasis patients in a phase Ib clinical study of TRX-4. TRX-4 has been awarded Orphan Drug status for recent-onset type 1 diabetes.
Brown
William M
WM
Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D016030:Kidney Transplantation; D010330:Patents as Topic; D011565:Psoriasis / Q000188:drug therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017252:CD3 Complex; C511937:TRX-4 monoclonal antibody